- Darwin Outgames calls for volunteersPosted 12 hours ago
- More DJs announced for official Mardi Gras PartyPosted 1 day ago
- Secretly filmed emotional coming out video to inspire othersPosted 1 day ago
- Gold, gold, gold for dragon boatersPosted 1 day ago
- Kelly Osbourne tweets Australian gay marriage supportPosted 1 day ago
- High Court overturns ACT’s same-sex marriage legislationPosted 1 day ago
- Women said something … now women will film somethingPosted 2 days ago
- Pride TV launches in AustraliaPosted 3 days ago
- Hey Tropfest! Us trans* are not fodder for award winning sexual manipulation “satire”Posted 3 days ago
- Twenty10′s new boss is ParadisePosted 3 days ago
PBS for Hep C treatment
Two new “groundbreaking” Hepatitis C virus (HCV) treatments will be subsidised under the Pharmaceutical Benefits Scheme for more than 130,000 patients annually. Federal Health Minister Tanya Plibersek announced boceprevir (Victrelis) and telaprevir (Incivo) would be available to people over 18-years-old with a certain type of HCV (genotype 1).
Subsidising the two treatments cost more than $220 million over five years.
It was estimated in 2011 more than 300,000 Australians had been exposed to HCV and at least 220,000 were living with chronic Hepatitis C.
Last year, Australian infectious diseases expert Dr Joe Sasadeusz from the Royal Melbourne Hospital said there was emerging evidence that showed HCV could be sexually transmitted between HIV-positive men.
It was estimated up to 30 per cent of HIV-positive men also had HCV.
HCV is one of the most commonly reported notifiable diseases in Australia.